[go: up one dir, main page]

MX2009002439A - Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos. - Google Patents

Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos.

Info

Publication number
MX2009002439A
MX2009002439A MX2009002439A MX2009002439A MX2009002439A MX 2009002439 A MX2009002439 A MX 2009002439A MX 2009002439 A MX2009002439 A MX 2009002439A MX 2009002439 A MX2009002439 A MX 2009002439A MX 2009002439 A MX2009002439 A MX 2009002439A
Authority
MX
Mexico
Prior art keywords
processes
preparation
benzoic acids
oxadiazole benzoic
oxadiazole
Prior art date
Application number
MX2009002439A
Other languages
English (en)
Inventor
Young-Choon Moon
Neil G Almstead
Peter Seongwoo Hwang
James J Takasugi
Seemon Pines
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2009002439A publication Critical patent/MX2009002439A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente se proporcionan los procesos para la preparación de compuestos útiles para el tratamiento, prevención o manejo de enfermedades asociadas con una mutación sin sentido. Más específicamente, se proporcionan en la presente procesos para la síntesis de 1,2,4-oxadiazoles. En particular se proporcionan en la presente procesos útiles en lal preparación de ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzóico.
MX2009002439A 2006-09-08 2007-09-06 Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos. MX2009002439A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84359506P 2006-09-08 2006-09-08
PCT/US2007/019561 WO2008030570A1 (en) 2006-09-08 2007-09-06 Processes for the preparation of 1,2,4-oxadiazole benzoic acids

Publications (1)

Publication Number Publication Date
MX2009002439A true MX2009002439A (es) 2009-03-27

Family

ID=38935880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002439A MX2009002439A (es) 2006-09-08 2007-09-06 Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos.

Country Status (24)

Country Link
US (2) US7678922B2 (es)
EP (1) EP2059513B1 (es)
JP (2) JP5955494B2 (es)
KR (1) KR101466368B1 (es)
CN (1) CN101535284B (es)
AR (3) AR062715A1 (es)
AU (1) AU2007292915B2 (es)
BR (1) BRPI0716996B8 (es)
CA (2) CA2842625C (es)
CL (1) CL2007002606A1 (es)
DK (1) DK2059513T3 (es)
ES (1) ES2404348T3 (es)
IL (1) IL197445A (es)
MX (1) MX2009002439A (es)
MY (1) MY148598A (es)
NZ (2) NZ598012A (es)
PE (2) PE20080771A1 (es)
PL (1) PL2059513T3 (es)
PT (1) PT2059513E (es)
RU (1) RU2495030C2 (es)
TW (1) TWI482761B (es)
UA (1) UA99265C2 (es)
WO (1) WO2008030570A1 (es)
ZA (1) ZA200901782B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887054T3 (es) 2003-04-11 2021-12-21 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
DK1874306T3 (da) 2005-04-08 2012-10-01 Ptc Therapeutics Inc Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi
IN2014CN04406A (es) * 2006-03-30 2015-09-04 Ptc Therapeutics Inc
BRPI0716996B8 (pt) * 2006-09-08 2021-05-25 Ptc Therapeutics Inc processo para preparar um composto
WO2008130370A1 (en) 2006-09-25 2008-10-30 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
US7863456B2 (en) * 2006-09-25 2011-01-04 Ptc Therapeutics, Inc. Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid
RU2462247C2 (ru) 2006-10-12 2012-09-27 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы дозирования перорально активного 1,2,4-оксадиазола для терапии, подавляющей нонсенс-мутацию
CN101714009A (zh) * 2009-05-14 2010-05-26 翁印嵩 集成通用电话功能的计算机
EP2668951B9 (en) 2011-01-25 2017-03-15 Viviabiotech, S.L. 1,2,4-oxadiazole derivatives as drugs modulating the glp-1 peptide receptor
ES2782509T3 (es) 2012-07-02 2020-09-15 Monsanto Technology Llc Procedimiento para la preparación de 1,2,4-oxadiazoles 3,5-disustituidos
WO2015134711A1 (en) 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技(台州)有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
CN108348527A (zh) 2015-10-30 2018-07-31 Ptc医疗公司 用于治疗癫痫的方法
TW201808922A (zh) 2016-06-20 2018-03-16 台灣神隆股份有限公司 製備阿塔魯仁及其中間體的方法
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
KR20210151131A (ko) 2019-04-10 2021-12-13 피티씨 테라퓨틱스, 인크. 소아 환자에서 넌센스 돌연변이 매개된 뒤센 근이영양증의 치료 방법
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN113045510B (zh) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 一种阿塔鲁伦的制备方法
CN114920667B (zh) * 2022-06-30 2024-06-21 湖南大学 一种阿塔鲁伦酯的电化学制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801509A1 (de) * 1978-01-12 1979-07-19 Schering Ag 1,2,4-oxadiazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende selektive herbizide mittel
DE3905242A1 (de) * 1989-02-21 1990-08-23 Basf Ag Verfahren zur herstellung von phenyloxdiazolylanilinen
NZ234760A (en) * 1989-08-18 1991-09-25 Sterling Drug Inc Antiviral oxazole compounds and compositions
DE4425794A1 (de) * 1994-07-21 1996-01-25 Basf Ag Nitrofarbstoffe
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AU2002313633B2 (en) 2001-06-08 2007-03-01 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
JP2006506340A (ja) 2002-08-09 2006-02-23 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体5のモジュレーターとしてのオキサジアゾール
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
ES2887054T3 (es) * 2003-04-11 2021-12-21 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
DK1874306T3 (da) 2005-04-08 2012-10-01 Ptc Therapeutics Inc Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi
BRPI0716996B8 (pt) * 2006-09-08 2021-05-25 Ptc Therapeutics Inc processo para preparar um composto

Also Published As

Publication number Publication date
RU2495030C2 (ru) 2013-10-10
AR062715A1 (es) 2008-11-26
PE20080771A1 (es) 2008-06-13
RU2009113019A (ru) 2010-10-20
CA2842625A1 (en) 2008-03-13
ES2404348T3 (es) 2013-05-27
CN101535284A (zh) 2009-09-16
AR107474A2 (es) 2018-05-02
BRPI0716996B1 (pt) 2021-02-09
US20100063297A1 (en) 2010-03-11
IL197445A (en) 2014-01-30
US7678922B2 (en) 2010-03-16
KR101466368B1 (ko) 2014-11-27
AU2007292915B2 (en) 2012-07-26
JP5955494B2 (ja) 2016-07-20
US20080139818A1 (en) 2008-06-12
KR20090054464A (ko) 2009-05-29
CA2662749C (en) 2015-01-20
WO2008030570A1 (en) 2008-03-13
US8367841B2 (en) 2013-02-05
PE20120669A1 (es) 2012-06-01
EP2059513A1 (en) 2009-05-20
ZA200901782B (en) 2010-06-30
CA2662749A1 (en) 2008-03-13
JP2014193896A (ja) 2014-10-09
EP2059513B1 (en) 2013-01-23
BRPI0716996A2 (pt) 2013-10-08
NZ575511A (en) 2012-02-24
CN101535284B (zh) 2014-12-10
UA99265C2 (ru) 2012-08-10
TWI482761B (zh) 2015-05-01
AU2007292915A1 (en) 2008-03-13
HK1134094A1 (en) 2010-04-16
JP2010502715A (ja) 2010-01-28
CA2842625C (en) 2016-07-12
TW200823180A (en) 2008-06-01
DK2059513T3 (da) 2013-05-06
NZ598012A (en) 2013-08-30
PL2059513T3 (pl) 2013-06-28
AR118922A2 (es) 2021-11-10
CL2007002606A1 (es) 2008-04-18
MY148598A (en) 2013-05-15
PT2059513E (pt) 2013-04-30
BRPI0716996B8 (pt) 2021-05-25
IL197445A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
MX2009002439A (es) Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos.
MX2009003909A (es) Métodos para dosificar un compuesto 1,2,4, - oxadiazol oralmente activo para el tratamiento de supresión de la mutación finalizadora.
EP2076501B8 (en) Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
WO2008011453A3 (en) SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
HRP20130891T1 (en) DGAT inhibitor
NO20075682L (no) Sammensetninger omfattende et oralt aktivt 1,2,4-oksadiazol for nonsense mutasjonsundertrykkelsesterapi
WO2007039122A3 (de) Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
NZ593969A (en) Pyrazine derivatives useful as inhibitors of atr kinase
GEP20115176B (en) Prodrug of cinnamide compound
HUE059464T2 (hu) 1,2,4-Oxadiazolbenzoesav-vegyületek és ezek alkalmazása nonsense szuppresszióhoz és betegségek kezelésére
ZA201003965B (en) 1,2,4-oxadiazole compounds for the treatment of autoimmune diseases
WO2010123959A3 (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
GEP20115309B (en) Acid addition salts, hydrates and polymorphs of 5-(2,4-dihy-droxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-arboxylic acid ethylamide and formulations comprising these forms
MX2009005619A (es) Formas poliformicas del deferasirox (icl670a).
CY1113938T1 (el) Διαδικασιες για την παρασκευη 1,2,4-οξαδιαζολο βενζοϊκων οξεων
HK1131919A (en) Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
HK1141807A (en) 1, 2, 4 -oxadiazole compounds for the treatment of autoimmune diseases
SI2111401T1 (sl) 4-š4-Š(š3-terc.butil-1-Š3-(hidroksimetil)fenilĆ-1H-pirazol-5-ilćkarba- moil)-aminoĆ-3-fluorofenoksić-N-metilpiridin-2-karboksamid kot tudi njegova predzdravila in soli za zdavljenje raka

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general